Insufficient scRNA-seq data for expression of CMPK2 at single-cell level.
Insufficient scRNA-seq data for expression of CMPK2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 99% | 263.94 | 326 / 328 | 91% | 12.85 | 162 / 178 |
lung | 100% | 747.67 | 577 / 578 | 90% | 13.16 | 1042 / 1155 |
breast | 99% | 451.14 | 456 / 459 | 90% | 16.76 | 1008 / 1118 |
stomach | 98% | 292.19 | 351 / 359 | 91% | 12.63 | 260 / 286 |
uterus | 99% | 267.32 | 169 / 170 | 88% | 16.31 | 406 / 459 |
ovary | 93% | 187.56 | 168 / 180 | 92% | 19.76 | 397 / 430 |
thymus | 98% | 341.34 | 643 / 653 | 86% | 6.14 | 521 / 605 |
esophagus | 90% | 250.91 | 1297 / 1445 | 94% | 18.90 | 172 / 183 |
adrenal gland | 100% | 412.16 | 257 / 258 | 82% | 11.84 | 188 / 230 |
intestine | 99% | 335.58 | 958 / 966 | 82% | 10.39 | 432 / 527 |
bladder | 95% | 220.05 | 20 / 21 | 84% | 12.84 | 425 / 504 |
brain | 90% | 434.29 | 2376 / 2642 | 80% | 8.77 | 562 / 705 |
prostate | 99% | 249.05 | 242 / 245 | 63% | 4.86 | 318 / 502 |
kidney | 93% | 393.21 | 83 / 89 | 68% | 6.26 | 613 / 901 |
liver | 89% | 212.57 | 201 / 226 | 53% | 4.61 | 217 / 406 |
skin | 41% | 66.74 | 741 / 1809 | 59% | 6.91 | 279 / 472 |
spleen | 100% | 617.10 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 490.81 | 1197 / 1204 | 0% | 0 | 0 / 0 |
heart | 96% | 271.83 | 830 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 19.87 | 42 / 45 |
peripheral blood | 86% | 600.41 | 802 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 86% | 227.87 | 1145 / 1335 | 0% | 0 | 0 / 0 |
muscle | 83% | 136.88 | 668 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 62% | 7.05 | 18 / 29 |
eye | 0% | 0 | 0 / 0 | 25% | 1.64 | 20 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0046940 | Biological process | nucleoside monophosphate phosphorylation |
GO_0006227 | Biological process | dUDP biosynthetic process |
GO_0006233 | Biological process | dTDP biosynthetic process |
GO_0006235 | Biological process | dTTP biosynthetic process |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0004127 | Molecular function | (d)CMP kinase activity |
GO_0033862 | Molecular function | UMP kinase activity |
GO_0036430 | Molecular function | CMP kinase activity |
GO_0004550 | Molecular function | nucleoside diphosphate kinase activity |
GO_0036431 | Molecular function | dCMP kinase activity |
GO_0004798 | Molecular function | thymidylate kinase activity |
GO_0005524 | Molecular function | ATP binding |
Gene name | CMPK2 |
Protein name | UMP-CMP kinase 2, mitochondrial (EC 2.7.4.14) (Nucleoside-diphosphate kinase) (EC 2.7.4.6) Mitochondrial cytidine monophosphate (UMP-CMP) kinase 2 |
Synonyms | |
Description | FUNCTION: Mitochondrial nucleotide monophosphate kinase needed for salvage dNTP synthesis that mediates immunomodulatory and antiviral activities through IFN-dependent and IFN-independent pathways . Restricts the replication of multiple viruses including flaviviruses or coronaviruses . Together with viperin/RSAD2 and ddhCTP, suppresses the replication of several coronaviruses through inhibition of the viral RNA-dependent RNA polymerase activities . Concerning flaviviruses, restricts RNA translation when localized to the mitochondria independently of its kinase activity . Is able to phosphorylate dUMP, dCMP, CMP, UMP and monophosphates of the pyrimidine nucleoside analogs ddC, dFdC, araC, BVDU and FdUrd with ATP as phosphate donor. Efficacy is highest for dUMP followed by dCMP while CMP and UMP are poor substrates. Controls therefore mitochondrial DNA synthesis by supplying required deoxyribonucleotides (By similarity). CMPK2-dependent mitochondrial DNA synthesis is necessary for the production of oxidized mitochondrial DNA fragments after exposure to NLRP3 activators (By similarity). In turn, cytosolic oxidized mtDNA associates with the NLRP3 inflammasome complex and is required for its activation (By similarity). . |
Accessions | ENST00000256722.10 [Q5EBM0-1] Q5EBM0 ENST00000404168.1 [Q5EBM0-4] I1Z9C7 ENST00000458098.5 [Q5EBM0-3] |